Oruka Therapeutics
ORKA
22 hedge funds and large institutions have $12.7M invested in Oruka Therapeutics in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 5 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
0.19% less ownership
Funds ownership: 4.32% → 4.14% (-0.19%)
0% less capital invested
Capital invested by funds: $12.7M → $12.7M (-$35.6K)
12% less funds holding
Funds holding: 25 → 22 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$21.1K |
| 2 |
Renaissance Technologies
New York
|
+$13.9K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$338 |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$219 |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$80 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
-$458K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$20.6K |
| 3 |
State Street
Boston,
Massachusetts
|
-$18.9K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$8.45K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$1.92K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Osaic Holdings
Scottsdale,
Arizona
| – | -$93 | -5 | Closed |
|
ORKA Hedge Fund Activity: Q1 2024 in Review
22 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q1 2024, worth a combined $12.7M — down 0.28% from $12.7M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ORKA and 2 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 4 added.
The largest buyer was HRT Financial, opening a new position worth an estimated $21.1K. The largest seller was Newtyn Management, exiting entirely with an estimated $458K sold.
- 22 institutional investors held Oruka Therapeutics (ORKA) as of Q1 2024, down from 25 in Q4 2023.
- Funds reported $12.7M of Oruka Therapeutics stock for Q1 2024, down 0.28% quarter-over-quarter.
- 2 funds opened new Oruka Therapeutics positions in Q1 2024 and 5 closed out, a net change of -3 holders.
- The largest Oruka Therapeutics buyer in Q1 2024 was HRT Financial, an estimated $21.1K added.
- The largest Oruka Therapeutics seller in Q1 2024 was Newtyn Management, an estimated $458K sold.
Based on aggregated 13F filings for Q1 2024.